Pipeline & Targets
Our FGFR-focused pipeline
Tyra is developing next-generation, oral, small-molecule precision medicines targeting FGFR biology. FGFR alterations occur in roughly 7% of cancers; our candidates are designed for FGFR-selectivity and to work around acquired resistance.
Investigational; not approved by the FDA or any health authority. Trial status is retrieved from clinicaltrials.gov; where an NCT identifier is not yet listed here, the link runs a search for the study.